Onco Aura, Dispositif Spécifique Régional Du Cancer

Onco Aura, Dispositif Spécifique Régional Du Cancer company information, Employees & Contact Information

Plusieurs missions sont confiées au Dispositif Spécifique Régional du Cancer Auvergne-Rhône-Alpes : - Contribuer à la coordination de l’organisation régionale de l’offre de soins en cancérologie et à sa lisibilité. - Promouvoir la qualité et la sécurité des traitements des patients atteints de cancer. - Développer l’expertise et l’expérimentation de projets communs innovants et accompagner les évolutions de l’offre de soins. - Contribuer à l’information et à la formation des acteurs, des patients et de leurs proches sur le parcours de santé en cancérologie.
Looking for a particular Onco Aura, Dispositif Spécifique Régional Du Cancer employee's phone or email?

Onco Aura, Dispositif Spécifique Régional Du Cancer Questions

News

FDA Approval of INLEXZO for BCG-Unresponsive Bladder Cancer - Oncodaily

FDA Approval of INLEXZO for BCG-Unresponsive Bladder Cancer Oncodaily

12 new breakthroughs in the fight against cancer - The World Economic Forum

12 new breakthroughs in the fight against cancer The World Economic Forum

Does Sunscreen Cause Cancer? Myths and Facts - Oncodaily

Does Sunscreen Cause Cancer? Myths and Facts Oncodaily

ONCAURA WELLNESS CENTER OFFICIALLY LAUNCHED IN MANZINI, PIONEERING HOLISTIC CANCER CARE IN ESWATINI - Eswatini Positive News

ONCAURA WELLNESS CENTER OFFICIALLY LAUNCHED IN MANZINI, PIONEERING HOLISTIC CANCER CARE IN ESWATINI Eswatini Positive News

PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities - Frontiers

PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities Frontiers

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance - Journal of Hematology & Oncology

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance Journal of Hematology & Oncology

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies - ScienceDirect.com

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies ScienceDirect.com

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer | British Journal of Cancer - Nature

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer | British Journal of Cancer Nature

Breast cancer: New blood test can predict return, researchers say - BBC

Breast cancer: New blood test can predict return, researchers say BBC

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer The New England Journal of Medicine

Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review - Wiley Online Library

Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review Wiley Online Library

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis - Frontiers

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis Frontiers

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer - ScienceDirect.com

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer ScienceDirect.com

Moving Breast Cancer Therapy up a Notch - Frontiers

Moving Breast Cancer Therapy up a Notch Frontiers

Sabine Brookman-May joins Aura Biosciences as Therapeutic Area Head, Urologic Oncology - Oncodaily

Sabine Brookman-May joins Aura Biosciences as Therapeutic Area Head, Urologic Oncology Oncodaily

Liposome-based diagnostic and therapeutic applications for pancreatic cancer - ScienceDirect.com

Liposome-based diagnostic and therapeutic applications for pancreatic cancer ScienceDirect.com

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review - Frontiers

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review Frontiers

Early results from a Phase 1 trial of Aura Biosciences drug bel-sar (AU-011) - Oncodaily

Early results from a Phase 1 trial of Aura Biosciences drug bel-sar (AU-011) Oncodaily

ctDNA as a cancer biomarker: A broad overview - ScienceDirect.com

ctDNA as a cancer biomarker: A broad overview ScienceDirect.com

Cholesterol in the ciliary membrane as a therapeutic target against cancer - Frontiers

Cholesterol in the ciliary membrane as a therapeutic target against cancer Frontiers

Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges - Frontiers

Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges Frontiers

Emerging therapies for non-small cell lung cancer - Journal of Hematology & Oncology

Emerging therapies for non-small cell lung cancer Journal of Hematology & Oncology

The anti-cancer effectiveness of some heterocyclic compounds containing sulfur atom - ScienceDirect.com

The anti-cancer effectiveness of some heterocyclic compounds containing sulfur atom ScienceDirect.com

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study - The Lancet

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study The Lancet

Localising BRCA gene mutations to better treat ovarian cancer - Institut Curie - Espace presse

Localising BRCA gene mutations to better treat ovarian cancer Institut Curie - Espace presse

Top Onco Aura, Dispositif Spécifique Régional Du Cancer Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant